Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.67 |
| ▸ | CTSB | P07858 | 3/20 | 0.67 |
| ▸ | CTSS | P25774 | 3/20 | 0.67 |
| ▸ | CTSK | P43235 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | KDM1A | O60341 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TACR1 | P25103 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1709147 | 1.00 | CTSL (0.67) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL7220623 | 1.00 | CTSL (0.67) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL19017976 | 0.90 | CTSK (0.55) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL7919838 | 0.90 | CTSK (0.55) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL13949513 | 0.90 | CTSL (0.55) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL12406443 | 0.90 | CTSK (0.56) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL4228130 | 0.90 | CTSL (0.55) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL3709555 | 0.90 | CTSK (0.55) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL5859423 | 0.90 | CTSL (0.56) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL13724915 | 0.89 | CASP1 (0.57) | CTSLCTSBCTSSCTSKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10632210-B2 | Peptidomimetic compounds and antibody-drug conjugates thereof | GENENTECH, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190083643-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-9657058-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160347792-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-12-01 | — | — | US | disclosed |
| US-20160347792-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-12-01 | — | — | US | disclosed |
| US-20160279261-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160279261-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2016-09-29 | — | — | US | disclosed |
| US-9441012-B2 | Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors | TRILLIUM THERAPEUTICS INC. (CA) | 2016-09-13 | — | — | US | disclosed |
| US-9441012-B2 | Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors | TRILLIUM THERAPEUTICS INC. (CA) | 2016-09-13 | — | — | US | disclosed |
| WO-2016011088-A2 | EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION | CENTRAX INTERNATIONAL, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| US-5484926-A | VIRICIDES AND ENZYME INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-01-16 | — | — | US | disclosed |
| EP-0652009-A1 | Identification and use of protease inhibitors | ELI LILLY AND COMPANY (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1995009843-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-04-13 | — | — | WO | disclosed |
| EP-0609625-A1 | Inhibitors of HIV protease useful for the treatment of AIDS | ELI LILLY AND COMPANY (US) | 1994-08-10 | — | — | EP | disclosed |
| EP-0604184-A1 | Inhibitors of HIV protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
| EP-0604182-A2 | Inhibitors of HIV protease useful for the treatment of Aids | ELI LILLY AND COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
| EP-0604186-A1 | Inhibitors of HIV protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
| EP-0526009-A1 | Inhibitors of hiv protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1993-02-03 | — | — | EP | disclosed |
| EP-0363284-A2 | Use of peptidase inhibitors for the preparation of medicaments useful for the treatment of strokes | MERRELL PHARMACEUTICALS INC. (US) | 1990-04-11 | — | — | EP | disclosed |
| EP-0361341-A2 | Therapeutics for aids based on inhibitors of HIV protease | MILES INC. (US) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347792-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | PSMB5, PSMB1, PSMB7 | CTSL 2486/4885CTSB 441/4885CTSS 1116/4885 |
| US-10632210-B2 | Peptidomimetic compounds and antibody-drug conjugates thereof | DNPEP, LNPEP, BCR | CTSL 311/4885CTSB 726/4885CTSS 1649/4885 |
| US-20190083643-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | DNPEP, LNPEP, BCR | CTSL 311/4885CTSB 726/4885CTSS 1649/4885 |
| US-20160279261-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | DNPEP, LNPEP, BCR | CTSL 311/4885CTSB 726/4885CTSS 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.